STOCK TITAN

Novan Inc - NOVN STOCK NEWS

Welcome to our dedicated news page for Novan (Ticker: NOVN), a resource for investors and traders seeking the latest updates and insights on Novan.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Novan's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Novan's position in the market.

Rhea-AI Summary
Ligand Pharmaceuticals has offered to acquire the assets of Novan for $15 million in cash and provide up to $15 million in debtor-in-possession financing. The transaction aims to preserve the value of Novan's business and berdazimer gel development assets. Ligand plans to out license or sell Novan's existing programs and commercial assets if the bid is successful. The proposed transaction is subject to court approval and is expected to close in Q3 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.34%
Tags
-
Rhea-AI Summary
Novan, Inc. and Ligand Pharmaceuticals have signed an agreement for the sale of Novan's assets under bankruptcy, with Ligand providing $15 million in financing. The agreement allows for the potential approval of berdazimer gel to treat molluscum contagiosum. The company continues to operate as a debtor-in-possession under Chapter 11. The sale is subject to bankruptcy court approval.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-70.54%
Tags
none
-
Rhea-AI Summary
Novan, Inc. will host its 2023 Annual Meeting of Stockholders on June 6, 2023, in a virtual format. The Chairman, President, and CEO, Paula Brown Stafford, will provide a corporate update after the meeting, including the Company's current focus and plans. The webcast can be accessed at www.virtualshareholdermeeting.com/NOVN2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.77%
Tags
none
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-17.65%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.38%
Tags
-
Rhea-AI Summary
Novan, Inc. will report its Q1 2023 financial results on May 15th and host a conference call to discuss the results. The call will be led by President and CEO Paula Brown Stafford.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.63%
Tags
conferences earnings
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.81%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.75%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.11%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.26%
Tags
conferences earnings
Novan Inc

Nasdaq:NOVN

NOVN Rankings

NOVN Stock Data

2.64M
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
Morrisville

About NOVN

novan, inc. is a clinical-stage biotechnology company focused on leveraging nitric oxide’s natural antiviral and immunomodulatory mechanisms of action to treat dermatological and oncovirus-mediated diseases. we believe that our ability to conveniently deploy nitric oxide in a solid form, on demand and in localized formulations allows us the potential to significantly improve patient outcomes in a variety of diseases.